Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
- Clinical Momentum and Platform Validation Drive Undervalued Upside at Werewolf Therapeutics
- Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities
- Werewolf Therapeutics provides pipeline update, review of INDUKINE data
- Werewolf Therapeutics announces 2025 priorities